NEOIMMUNETECH
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics.
NEOIMMUNETECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.neoimmunetech.com
Total Employee:
1+
Status:
Active
Contact:
+82-31-709-5858
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Font Awesome Apache ReCAPTCHA GoDaddy DNS ReCAPTCHA V2
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-25 | NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer |
Official Site Inspections
http://www.neoimmunetech.com Semrush global rank: 7.05 M Semrush visits lastest month: 617
- Host name: ec2-43-200-231-7.ap-northeast-2.compute.amazonaws.com
- IP address: 43.200.231.7
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "NeoImmuneTech"
NeoImmuneTech
Neoimmunetech, ๋ค์ค์ด๋ฎจํ , ํญ์์ฑ ์ธํฌ ์ฆ์, ์ข ์ ๋ด ๋ฆผํ๊ตฌ ์ฆ๊ฐ, T์ธํฌ ์์ฉ์ฒด์ ํด๋ก ์ฑ ์ฆ๊ฐ, T์ธํฌ์ ์ค๊ธฐ์ธํฌ ํน์ฑ์ ์ ๋, ํ ํญ์ modality์์ ๋๋ฐ์์น ํจ๋ฅSee details»
NeoImmuneTech - Crunchbase Company Profile & Funding
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious โฆSee details»
NeoImmuneTech
Founded in 2014 in Rockville, Maryland, NeoImmuneTech is a biotechnology company focused on developing T cell-based therapeutics, particularly NT-I7 (efineptakin alfa), to treat cancer โฆSee details»
ํ์ฌ์๊ฐ - neoimmunetech.com
Neoimmunetech, ๋ค์ค์ด๋ฎจํ , ํญ์์ฑ ์ธํฌ ์ฆ์, ์ข ์ ๋ด ๋ฆผํ๊ตฌ ์ฆ๊ฐ, T์ธํฌ ์์ฉ์ฒด์ ํด๋ก ์ฑ ์ฆ๊ฐ, T์ธํฌ์ ์ค๊ธฐ์ธํฌ ํน์ฑ์ ์ ๋, ํ ํญ์ modality์์ ๋๋ฐ์์น ํจ๋ฅSee details»
Company profile: NeoImmuneTech - pharmaphorum
Jan 29, 2014 About NeoImmuneTech, Inc. Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to expanding the horizon of immuno-oncology ...See details»
NeoImmuneTech - LinkedIn
NeoImmuneTech | 1,586 followers on LinkedIn. NIT is a clinical-stage T cell-focused biotech company dedicated to expanding the horizon of I-O and infectious diseases | โฆSee details»
NeoImmuneTech - Overview, News & Similar companies - ZoomInfo
Who is NeoImmuneTech. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and e โฆSee details»
NeoImmuneTech Company Profile - Craft
NeoImmuneTech (NIT) is a biotech company developing immunotherapeutics for cancer and infectious diseases. It develops NT-I7, a T-cell amplifier that enhances immune functions. The โฆSee details»
NeoImmuneTech Company Profile 2025: Stock โฆ
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to โฆSee details»
Neoimmunetech, Inc. Company Profile | Rockville, MD
Cash Flow (mil) 2023 2022 2021; Net Operating Cash-$49,761 -$42,405 -$33,887 Net Investing Cash: $2,087 -$3,150See details»
NeoImmuneTech - VentureRadar
Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno โฆSee details»
NeoImmuneTech Welcomes a New President for its Development โฆ
Jan 15, 2024 NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to โฆSee details»
NeoImmuneTech - Tech Stack, Apps, Patents & Trademarks
Dec 1, 2024 NeoImmuneTech is a biotech company developing T cell-centered novel immunotherapeutics.See details»
NeoImmuneTech, Inc. - Drug pipelines, Patents, Clinical trials
NeoImmuneTech's CEO, Luke Oh, PhD, said: "We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat โฆSee details»
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 โฆ
Nov 20, 2023 A contract research organization (CRO) under contract to National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is โฆSee details»
ํํธ๋์ญ - neoimmunetech.com
Neoimmunetech, ๋ค์ค์ด๋ฎจํ , ํญ์์ฑ ์ธํฌ ์ฆ์, ์ข ์ ๋ด ๋ฆผํ๊ตฌ ์ฆ๊ฐ, T์ธํฌ ์์ฉ์ฒด์ ํด๋ก ์ฑ ์ฆ๊ฐ, T์ธํฌ์ ์ค๊ธฐ์ธํฌ ํน์ฑ์ ์ ๋, ํ ํญ์ modality์์ ๋๋ฐ์์น ํจ๋ฅSee details»
Working at NeoImmuneTech, Inc.: 3 Reviews - Indeed
Oct 24, 2024 Working at NeoImmuneTech Inc. offers a dynamic and innovative environment, driven by cutting-edge biotechnology. Employees appreciate the collaborative culture, growth โฆSee details»
๊ฐ๋ฐํํฉ - neoimmunetech.com
NeoImmuneTech is committed to developing innovative treatments and ensuring access to investigational therapies for patients with serious or life-threatening conditions who lack โฆSee details»
NeoImmuneTech begins trial of primates for acute radiation โฆ
Dec 24, 2024 NeoImmuneTech has signed an agreement with U.S. contract research organization Charles River Laboratories International (CRL) to conduct a study of primates for โฆSee details»
๋ด์ค - neoimmunetech.com
December 7, 2024 โ ROCKVILLE, MD: NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, announced today the oral presentation of a study led by Duke โฆSee details»